Bevacizumab is a recombinant humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF), which specifically binds to VEGF to block its binding to its receptor, thus reducing angiogenesis, inducing the degeneration of existing blood vessels, inhibiting tumour formation, inhibiting immature angiogenesis, and inducing vascular normalization [24]. The gene discussed is VEGFA; the disease is neoplasm.